-
CCR Related Products (134)
Related Products (134)
-
TBK1 degrader-4
0 ImagesCat. No.: HY-176255TBK1 degrader-4 (Compound 30) is a molecular glue degrader targeting TBK1. TBK1 degrader-4 effectively inhibits cyst growth, alleviates inflammation, and reduces the levels of pro-inflammatory factors such as Ccl2, IFNβ, and IL-6. TBK1 degrader-4 is promising for research of autosomal dominant polycystic kidney disease (ADPKD).
-
Anti-CCL2 (Carlumab)-VcMMAE
0 ImagesCat. No.: HY-171683Anti-CCL2 (Carlumab)-VcMMAE is an antibody-drug conjugate (ADC) consisting of the humanized anti-CCL2 (chemokine ligand 2) antibody Carlumab (HY-P99188) conjugated with valine-citrulline (vc) and the tubulin inhibitor MMAE (HY-15162). The ADC toxic molecule and linker part are McMMAE (HY-15575). Anti-CCL2 (Carlumab)-VcMMAE induces apoptosis and can be used in cancer research.
-
BAY-3153
0 ImagesCat. No.: HY-148232CAS No.: 2771319-69-6BAY-3153, a chemical probe, is a selective CCR1 (C-C motif chemokine receptor 1) antagonist (human IC50=3 nM; rat IC50=11 nM; mice IC50=81 nM).
-
CCR6 antagonist 2
0 ImagesCat. No.: HY-172161CCR6 antagonist 2 (Compound 20c) is the antagonist for CCR6 with a Ki of 1.1 nM. CCR6 antagonist 2 inhibits CCL20-induced calcium ion influx (IC50 = 4.9 nM), inhibits the chemotactic migration of CCR6+ T cells (IC50 = 190 nM).
-
Anti-CCL21 Antibody
0 ImagesCat. No.: HY-P992197
-
LT166
0 ImagesCat. No.: HY-163761LT166 is a fluorescent ligand for CC chemokine receptor 1 (CCR1) with a KD of 1.90 μM.
-
Anti-CCR6 Antibody
0 ImagesCat. No.: HY-P991939
-
CH0076989
0 ImagesCat. No.: HY-136881CAS No.: 954371-52-9CH0076989 is a specific CCR3 agonist. CH0076989 activates eosinophils and transfectants expressing both wild-type CCR3 and a CCR1:CCR3 chimaeric receptor lacking the CCR3 amino-terminus. CH0076989 has a direct interaction with the transmembrane helices of CCR3, supported by the complete loss of its activity due to mutations of the residues Y41, Y113 and E287. CH0076989 can be used for the study of inflammation and allergic diseases (such as asthma).
-
PLS-123
0 ImagesCat. No.: HY-120406CAS No.: 1431727-04-6LPS-123 is a covalently irreversible BTK inhibitor with an IC50 of < 5 nM. LPS-123 simultaneously inhibits the catalytic activity of BTK at Tyr551 and its self-activation at Tyr223. LPS-123 inhibits phosphorylation of the AKT/mTOR and MAPK signaling pathways, activation of PLCγ2, ERK1/2, p38, AKT, and mTOR, and blocks the production of CCL3 and CCL4 chemokines. LPS-123 exhibits significant anti-proliferative activity against various B-cell lymphoma cell lines and effectively induces apoptosis via a caspase-dependent pathway. LPS-123 also demonstrates significant antitumor activity in the OCI-Ly7 xenograft model. LPS-123 can be used for lymphoma research.
-
Zn-DPA-maytansinoid conjugate 1
0 ImagesCat. No.: HY-151559CAS No.: 3034629-04-1Zn-DPA-maytansinoid conjugate 1 is a small molecule-based maytansinoid conjugate targeting immune checkpoint. Zn-DPA-maytansinoid conjugate 1 induces lasting regression of tumor growth and rejuvenates tumor microenvironment (TME) to an "inflamed hot tumor" .
-
Anti-CCR9 Antibody
0 ImagesCat. No.: HY-P992199
-
CCL17-IN-2
0 ImagesCat. No.: HY-185145CAS No.: 3104330-35-7CCL17-IN-2 (Compound Ex.128) is a CCL17 secretion inhibitor with an EC50 of 0.3 nM. CCL17-IN-1 can be used in the research of autoimmune diseases, dermatological conditions, and respiratory disorders.
-
TAK-661
0 ImagesCat. No.: HY-159927CAS No.: 175215-34-6TAK-661 is a inhibitor of eosinophil chemotaxis. TAK-661 significantly reduces the bronchoconstriction during the late phase, along with the inhibition of eosinophilia in bronchoalveolar lavage (BAL) and the eosinophil infiltration into the airway wall.
